Showing 3691-3700 of 4764 results for "".
- FDA Accepts NDAs for Review of Binimetinib And Encorafenib for Advanced BRAF-mutant Melanomahttps://practicaldermatology.com/news/fda-accepts-ndas-for-review-of-binimetinib-and-encorafenib-for-advanced-braf-mutant-melanoma/2458058/The FDA has accepted Array BioPharma's New Drug Applications (NDAs) to support use of the combination of binimetinib 45 mg twice daily and encorafenib 450 mg once daily (COMBO450) for the treatment of patients with BRAF-mutant advanced, unresectable or metastatic melanoma. The FDA se
- Two Galderma Rosacea Therapies Work Well Togetherhttps://practicaldermatology.com/news/two-galderma-rosacea-therapies-work-well-together/2458061/Combined use of Galderma’s SOOLANTRA (ivermectin1% Cream) and Mirvaso (Brimonidine 0.33% Gel) pack a one-two punch against the erythema and inflammatory lesions of rosacea, the MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCe
- Lilly to Present New Data for Olumiant® and Taltz® at EADVhttps://practicaldermatology.com/news/lilly-to-present-new-data-for-olumiant-and-taltz-eadv/2458060/Eli Lilly and Company will present Phase 2 safety and efficacy data evaluating Olumiant® (baricitinib) for the treatment of moderate-to-severe atopic dermatitis (Lilly and Incyte Corporation are partners on the develo
- Link Found Between a Molecular Driver of Melanoma Progression and Novel Therapeutic Agenthttps://practicaldermatology.com/news/link-found-between-a-molecular-driver-of-melanoma-progression-and-novel-therapeutic-agent/2458065/Research linking autophagy with the Wnt signaling pathway, a key regulator of melanoma progression and metastasis, may guide effective use of autophagy inhibitors. The findings appear online in Cancer Research. Autophagy allows cancer cells to survive under stressful cond
- AD Breakthrough? Medimetriks' MM36 Achieves Rapid Itch Relief, Safety in Phase 2 Studyhttps://practicaldermatology.com/news/ad-breakthrough-medimetriks-mm36-achieves-rapid-itch-relief-safety-in-phase-2-study/2458068/Medimetriks’ PDE4 inhibitor, MM36, appears to be safe, well-tolerated and provides rapid itch relief when applied twice daily to pediatric and adolescent atopic dermatitis (AD) patients, according to results of a Phase 2 study. The company ex
- Kyocera Begins Research in AI-based Image Recognition to Help Diagnose Skin Diseases and Cancers Via Smartphonehttps://practicaldermatology.com/news/kyocera-begind-research-in-ai-based-image-recognition-to-help-diagnose-skin-diseases-and-cancers-via-smartphone/2458070/Kyocera Corporation is partnering with the University of Tsukuba to develop Artificial Intelligence (AI)-based image recognition for eHealth applications to diagnose melanoma and other skin diseases by analyzing digital images of a patient’s skin.
- Psoriasis Severity Linked to Increased Risk of Deathhttps://practicaldermatology.com/news/psoriasis-severity-linked-to-increased-risk-of-death/2458074/The more surface area of the body covered by psoriasis, the greater the risk of death, according to a new analysis by researchers at the Perelman School of Medicine at the University of Pennsylvania. In fact, patients with psoriasis on 10 perce
- Abeona Therapeutics Receives FDA Breakthrough Therapy Designation for EB-101 Autologous Cell Therapy in EBhttps://practicaldermatology.com/news/abeona-therapeutics-receives-fda-breakthrough-therapy-designation-for-eb-101-autologous-cell-therapy-in-eb/2458075/The U.S. Food and Drug Administration granted Breakthrough Therapy Designation status to the Abeona Therapeutics Inc.’s EB-101 gene therapy program for patients with Recessive Dystrophic Epidermolysis Bullosa. EB-101 is an autologous,&
- WDS Offers Skin Cancer Screeningshttps://practicaldermatology.com/news/wds-to-offer-skin-cancer-screenings/2458077/The Women’s Dermatologic Society (WDS) Play Safe in the Sun Program is slated to par
- DermTech Appoints New Member to Board of Directorshttps://practicaldermatology.com/news/dermtech-appoints-new-members-to-board-of-directors/2458080/DermTech, Inc., appointed Herman “Herm” Rosenman to its Board of Directors. Mr. Rosenman, CPA, brings more than 30 years of public company operating and financial experience to DermTech. He received a B.B.A. in finance and accounting from Pace University and an M.B.A. in finance from